NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
93.31
-0.11 (-0.12%)
At close: 4:02PM EDT

94.17 +0.86 (0.92%)
Pre-Market: 7:30AM EDT

Stock chart is not supported by your current browser
Previous Close93.42
Open93.57
Bid94.14 x 1200
Ask94.23 x 800
Day's Range92.90 - 93.66
52 Week Range72.30 - 93.89
Volume1,363,662
Avg. Volume1,972,029
Market Cap214.242B
Beta (3Y Monthly)0.64
PE Ratio (TTM)17.34
EPS (TTM)5.38
Earnings DateN/A
Forward Dividend & Yield2.83 (3.03%)
Ex-Dividend Date2019-03-04
1y Target Est104.00
Trade prices are not sourced from all markets
  • Were Hedge Funds Right About Novartis AG  (NVS)?
    Insider Monkey13 hours ago

    Were Hedge Funds Right About Novartis AG (NVS)?

    As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and their long-term focus allows us to profit from the recent […]

  • Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more
    American City Business Journals22 hours ago

    Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more

    How Genentech — with the help of a $1.7 billion merger — is breaking new ground in cancer … and more in our Health Care Digest.

  • Moody'syesterday

    Alcon Inc. -- Moody's assigns Baa2 issuer rating to Alcon; stable outlook

    Moody's Investors Service has assigned a Baa2 long-term issuer rating to Alcon Inc. ("Alcon" or "the company"). This is the first time that Moody's assigned ratings to Alcon, a global manufacturer of eye care medical equipment and products which is being spun off from Novartis AG (Novartis, A1 stable).

  • Benzinga3 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

    Biotech stocks came under pressure last week despite two FDA approvals coming through. The FDA approved SAGE Therapeutics Inc (NASDAQ: SAGE )'s drug to treat postpartum depression and Jazz Pharmaceuticals ...

  • Conatus (CNAT) Declines on Failure of NASH Fibrosis Study
    Zacks4 days ago

    Conatus (CNAT) Declines on Failure of NASH Fibrosis Study

    Conatus' (CNAT) stock plunges as the phase IIb study on emricasan for the treatment of biopsy-confirmed NASH and liver fibrosis fails.

  • Biogen Stock Crashes on Termination of Alzheimer's Studies
    Zacks4 days ago

    Biogen Stock Crashes on Termination of Alzheimer's Studies

    Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.

  • Benzinga4 days ago

    Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo

    Shares of microcap biotech Conatus Pharmaceuticals Inc (NASDAQ: CNAT ) are heading crashing following the release of results from a midstage trial of its non-alcoholic steatohepatitis candidate. What Happened ...

  • Reuters4 days ago

    Novartis says listing of Alcon eye care business expected on April 9

    Shares in Alcon, the eye care business being spun-off by Novartis, are expected to start trading on April 9 on the Swiss market and the New York Stock Exchange, the Swiss pharmaceuticals company said on Friday. "Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange," Novartis said in a statement, adding that Alcon would enter the SMI, Switzerland's blue-chip stock index, on its first trading day. Novartis said Alcon had secured debt financing of $3.5 billion, adding that Bank of America Merrill Lynch and UBS were advising Novartis on the transaction.

  • Is Biogen a Bad-News Buy Now?
    Motley Fool5 days ago

    Is Biogen a Bad-News Buy Now?

    Now that the riskiest asset in biotech is off the table, it's time to reconsider an industry legend that's down 30% on Thursday.

  • Cooper Companies' (COO) CooperVision Gains Momentum Globally
    Zacks5 days ago

    Cooper Companies' (COO) CooperVision Gains Momentum Globally

    Cooper Companies (COO) maintains its leading position in the markets of specialty lenses, supported by highly exclusive products like Biofinity and Clariti.

  • Major biotech landlord plants flag in East Bay with acquisition of Novartis site
    American City Business Journals6 days ago

    Major biotech landlord plants flag in East Bay with acquisition of Novartis site

    As it builds out high-profile biotech developments on the Peninsula, BioMed Realty is digging into the East Bay in a big way. The San Diego-based unit of Blackstone Group LP (NYSE: BX) paid about $135 million for the six-story, 250,000-square-foot structure, the company said Wednesday, which includes an adjacent space for as much as 850,000 square feet of additional lab and office space. "We plan to offer in excess of 1 million square feet of space to innovative tenants, including biotech and other laboratory users," Denis Sullivan, executive vice president and chief investment officer for BioMed, said in a statement.

  • Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision
    Zacks6 days ago

    Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision

    The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.

  • Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
    Zacks6 days ago

    Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan

    Conatus (CNAT) concentrates on the development of its lead candidate, emricasan, for treating patients with fibrosis or cirrhosis caused by NASH.

  • Tilray Earnings Impressive: More Reasons to Buy Marijuana ETFs
    Zacks7 days ago

    Tilray Earnings Impressive: More Reasons to Buy Marijuana ETFs

    Tilray earnings results speak of bullishness, making things better for marijuana ETF investors.

  • 3 Blue-Chip Stocks That Just Hit 52-Week Highs: Are They Buys?
    Motley Fool7 days ago

    3 Blue-Chip Stocks That Just Hit 52-Week Highs: Are They Buys?

    Two medical-device makers and one big drugmaker are on a roll. But can their momentum continue?

  • Tilray Inc (TLRY) Q4 2018 Earnings Conference Call Transcript
    Motley Fool7 days ago

    Tilray Inc (TLRY) Q4 2018 Earnings Conference Call Transcript

    TLRY earnings call for the period ending December 31, 2018.

  • Alnylam's (ALNY) Impressive Pipeline Drives Share Price
    Zacks8 days ago

    Alnylam's (ALNY) Impressive Pipeline Drives Share Price

    Alnylam's (ALNY) share price increases on robust performance of pipeline candidates.

  • Novartis' (NVS) Alcon Acquired PowerVision for $285 Million
    Zacks8 days ago

    Novartis' (NVS) Alcon Acquired PowerVision for $285 Million

    Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.

  • Roche Gets Approval for Label Expansion of MabThera in Europe
    Zacks11 days ago

    Roche Gets Approval for Label Expansion of MabThera in Europe

    Roche (RHHBY) gets EC approval for the label expansion of its legacy RA drug, MabThera for pemphigus vulgaris.

  • Benzinga11 days ago

    The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 14) Novartis AG (NYSE: NVS ) (announced resignation of ...

  • Roche Receives EC Approval for Label Expansion of Hemlibra
    Zacks12 days ago

    Roche Receives EC Approval for Label Expansion of Hemlibra

    Roche (RHHBY) gets approval from European Commission for a label expansion of hemophilia drug, Hemlibra.

  • Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades
    Investopedia12 days ago

    Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades

    Shares of major drug makers including Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Amgen Inc. (AMGN), Novartis AG (NVS) and AbbVie Inc. (ABBV), are already dramatically lagging the broader market this year.

  • Novartis generics boss quits amid conjecture over business's future
    Reuters12 days ago

    Novartis generics boss quits amid conjecture over business's future

    Novartis's generics chief is quitting after the Swiss drugmaker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spin-off or sale. Richard Francis, Sandoz's boss since 2014, is stepping down, Novartis Chief Executive Vas Narasimhan said on Thursday, adding "Richard has decided that for personal reasons he cannot commit to stay with Sandoz until the transformation is completed". Francesco Balestrieri, head of Sandoz's Europe region, will become interim CEO to oversee what Narasimhan called "a multi-year transformation program" in which Sandoz re-focuses on biosimilars -- copies of patent-expired biological drugs made by rivals -- and hard-to-make generics like insulin.

  • Financial Times12 days ago

    [$$] Head of Novartis generic drugs business steps down

    The head of Novartis’s generic drugs business, Sandoz, has stepped down, sparking fresh speculation about its future. Vas Narasimhan, chief executive of the Swiss drugmaker, said that Richard Francis, who has run Sandoz for the past five years, had “decided that for personal reasons he cannot commit to stay with Sandoz” for the duration of “a multiyear transformation programme”. Mr Francis’ departure will revive speculation that Mr Narasimhan, who has sought to focus the company on its higher margin innovative medicines business since taking charge last year, is eyeing a potential spin-off of Sandoz.